vs
Side-by-side financial comparison of Allstate (ALL) and Amneal Pharmaceuticals, Inc. (AMRX). Click either name above to swap in a different company.
Allstate is the larger business by last-quarter revenue ($922.0M vs $722.5M, roughly 1.3× Amneal Pharmaceuticals, Inc.). Allstate runs the higher net margin — 266.6% vs 10.8%, a 255.8% gap on every dollar of revenue. On growth, Allstate posted the faster year-over-year revenue change (7.2% vs 3.9%). Over the past eight quarters, Amneal Pharmaceuticals, Inc.'s revenue compounded faster (1.5% CAGR vs -75.8%).
The Allstate Corporation, together with its subsidiaries, provides property and casualty, and other insurance products in the United States and Canada. The company operates through Allstate Protection; Protection Services; Allstate Health and Benefits; and Run-off Property-Liability segments. The Allstate Protection segment offers private passenger auto and homeowners insurance; specialty auto products, including motorcycle, trailer, motor home, and off-road vehicle insurance; other personal ...
Amneal Pharmaceuticals, Inc. is an American publicly traded pharmaceutical company that develops, manufactures and distributes generics and specialty pharmaceutical products. The company is headquartered in Bridgewater, New Jersey, and is one of the largest manufacturers of generic drugs in the United States.
ALL vs AMRX — Head-to-Head
Income Statement — Q1 FY2026 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $922.0M | $722.5M |
| Net Profit | $2.5B | $78.0M |
| Gross Margin | — | 44.3% |
| Operating Margin | -1400.3% | — |
| Net Margin | 266.6% | 10.8% |
| Revenue YoY | 7.2% | 3.9% |
| Net Profit YoY | — | 217.0% |
| EPS (diluted) | $9.25 | $0.19 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | $922.0M | $722.5M | ||
| Q4 25 | $17.3B | $814.3M | ||
| Q3 25 | $17.3B | $784.5M | ||
| Q2 25 | $16.6B | $724.5M | ||
| Q1 25 | $16.5B | $695.4M | ||
| Q4 24 | $16.5B | $730.5M | ||
| Q3 24 | $16.6B | $702.5M | ||
| Q2 24 | $15.7B | $701.8M |
| Q1 26 | $2.5B | $78.0M | ||
| Q4 25 | $3.8B | $35.1M | ||
| Q3 25 | $3.7B | $2.4M | ||
| Q2 25 | $2.1B | $22.4M | ||
| Q1 25 | $595.0M | $12.2M | ||
| Q4 24 | $1.9B | $-31.1M | ||
| Q3 24 | $1.2B | $-156.0K | ||
| Q2 24 | $331.0M | $6.0M |
| Q1 26 | — | 44.3% | ||
| Q4 25 | — | 36.5% | ||
| Q3 25 | — | 34.9% | ||
| Q2 25 | — | 39.5% | ||
| Q1 25 | — | 36.8% | ||
| Q4 24 | — | 36.0% | ||
| Q3 24 | — | 38.4% | ||
| Q2 24 | — | 35.6% |
| Q1 26 | -1400.3% | — | ||
| Q4 25 | — | 13.8% | ||
| Q3 25 | — | 9.0% | ||
| Q2 25 | — | 15.4% | ||
| Q1 25 | — | 14.4% | ||
| Q4 24 | — | 10.4% | ||
| Q3 24 | — | 12.6% | ||
| Q2 24 | — | 13.6% |
| Q1 26 | 266.6% | 10.8% | ||
| Q4 25 | 22.1% | 4.3% | ||
| Q3 25 | 21.7% | 0.3% | ||
| Q2 25 | 12.7% | 3.1% | ||
| Q1 25 | 3.6% | 1.8% | ||
| Q4 24 | 11.7% | -4.3% | ||
| Q3 24 | 7.2% | -0.0% | ||
| Q2 24 | 2.1% | 0.9% |
| Q1 26 | $9.25 | $0.19 | ||
| Q4 25 | $14.24 | $0.10 | ||
| Q3 25 | $13.95 | $0.01 | ||
| Q2 25 | $7.76 | $0.07 | ||
| Q1 25 | $2.11 | $0.04 | ||
| Q4 24 | $7.07 | $-0.10 | ||
| Q3 24 | $4.33 | $0.00 | ||
| Q2 24 | $1.13 | $0.02 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | — | — |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $31.6B | — |
| Total Assets | $124.0B | — |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | $4.9B | $282.0M | ||
| Q3 25 | $8.7B | $201.2M | ||
| Q2 25 | $9.6B | $71.5M | ||
| Q1 25 | $6.5B | $59.2M | ||
| Q4 24 | $4.5B | $110.6M | ||
| Q3 24 | $7.0B | $74.0M | ||
| Q2 24 | $5.3B | $43.8M |
| Q1 26 | — | — | ||
| Q4 25 | $7.5B | $2.6B | ||
| Q3 25 | $8.1B | $2.6B | ||
| Q2 25 | $8.1B | $2.2B | ||
| Q1 25 | $8.1B | $2.2B | ||
| Q4 24 | $8.1B | $2.4B | ||
| Q3 24 | $8.1B | $2.4B | ||
| Q2 24 | $8.1B | $2.4B |
| Q1 26 | $31.6B | — | ||
| Q4 25 | $30.6B | $-70.8M | ||
| Q3 25 | $27.5B | $-109.5M | ||
| Q2 25 | $24.0B | $-112.1M | ||
| Q1 25 | $22.1B | $-131.7M | ||
| Q4 24 | $21.4B | $-109.3M | ||
| Q3 24 | $20.9B | $-93.4M | ||
| Q2 24 | $18.6B | $-57.5M |
| Q1 26 | $124.0B | — | ||
| Q4 25 | $119.8B | $3.7B | ||
| Q3 25 | $120.4B | $3.6B | ||
| Q2 25 | $115.9B | $3.4B | ||
| Q1 25 | $115.2B | $3.4B | ||
| Q4 24 | $111.6B | $3.5B | ||
| Q3 24 | $113.7B | $3.5B | ||
| Q2 24 | $108.4B | $3.5B |
| Q1 26 | — | — | ||
| Q4 25 | 0.24× | — | ||
| Q3 25 | 0.29× | — | ||
| Q2 25 | 0.34× | — | ||
| Q1 25 | 0.37× | — | ||
| Q4 24 | 0.38× | — | ||
| Q3 24 | 0.39× | — | ||
| Q2 24 | 0.43× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
ALL
Segment breakdown not available.
AMRX
| Affordable Medicines net | $423.0M | 59% |
| AvKARE net | $166.0M | 23% |
| Specialty net | $133.0M | 18% |
